Clinical Significance of NPM1 A and Non A Mutations and Its Relation to The ARF/P53 Pathway in Egyptian Acute Myeloid Leukemia Patients
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 94 (1) , 27-33
Abstract
Background: Nucleophosmin 1 (NPM1) gene is known for its regulatory role of the ARF-p53-tumor suppressor pathway. Its mutations are known to be the most common gene mutations in AML. Aim: To detect the type of NPM1 gene mutation (NPM-A mut and non-A mut) in AML patients and correlating it with changes in molecular gene expression level of p53 and ARF genes also to study their relation to clinical, laboratory data and response to treatment. Methods: Absolute quantification of the NPM1 mutation type and the expression level of p53 and ARF genes were assessed using quantitative reverse-transcription PCR (RT-qPCR). Results: We studied 41 newly diagnosed AML patients, all of them had NPM1 gene mutation, out of them 25/41 had non-A mutation (61%) and 16/41 (39%) had mutation A. A statistically significant difference between AML patients with NPM1 mutation-A and non-A mutation was found in bone marrow blasts count (p-value=0.032). A trend statistical significance was observed in patients with NPM1 mutation-A and P53 gene overexpression than in patients with non-A mutation as well as ARF gene expression for patients with NPM1 mutation-A is higher than patients with non-A mutation (p-value=0.063). Median follow up of patients’ cohort was 1.81 (0.03-47.1) months. Median survival duration for patients carrying NPM1 mutation-A compared to those with other NPM1 mutations was 1.09 months versus 1.05 months, and this variation lacked statistical significance (p-value of 0.634). Conclusion: We can conclude that there is a trend statistically association between p53 and ARF genes high expression level and NPM1 mut-A type. It is important to detect the type of NPM1 mutation with examination of P53 and ARF genes expression to help in therapeutic strategies.Keywords
This publication has 32 references indexed in Scilit:
- When the good go bad: Mutant NPM1 in acute myeloid leukemiaBlood Reviews, 2018
- Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemiaLeukemia Research, 2017
- Biological and clinical consequences of NPM1 mutations in AMLLeukemia, 2017
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’Blood Cancer Journal, 2016
- Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal HemopoiesisCell Reports, 2015
- Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalizationProtein Science, 2013
- Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expressionClinica Chimica Acta, 2008
- Cooperating gene mutations in acute myeloid leukemia: a review of the literatureLeukemia, 2008
- Modeling the Therapeutic Efficacy of p53 Restoration in TumorsCell, 2006
- Role of nucleophosmin in embryonic development and tumorigenesisNature, 2005